The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1704
June 10, 2024
View Complete Issue         Table of Contents 2019 
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
June 10, 2024 (Issue: 1704)
Eohilia (Takeda), an oral suspension formulation of the corticosteroid budesonide, has been approved by the FDA for treatment of eosinophilic esophagitis (EoE) in patients ≥11 years old. It is the first oral drug to be approved in the US for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
Article code: 1704c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.